Top and Current
Source: (remove) : Do Kim
RSSJSONXMLCSV
Top and Current
Source: (remove) : Do Kim
RSSJSONXMLCSV
Tue, February 21, 2023
Wed, February 8, 2023
Thu, January 19, 2023
Wed, January 11, 2023
Mon, December 12, 2022
Fri, October 14, 2022
Wed, August 17, 2022
Tue, July 26, 2022
Fri, July 15, 2022
Thu, June 23, 2022
Tue, May 17, 2022
Wed, May 11, 2022
Fri, May 6, 2022
Fri, April 22, 2022
Thu, March 31, 2022
Fri, November 19, 2021
Tue, February 2, 2021
Mon, January 25, 2021
Tue, January 5, 2021
Fri, December 18, 2020
Thu, May 7, 2020
Thu, April 30, 2020
Mon, November 25, 2019
Thu, November 21, 2019
Thu, May 2, 2019
Mon, April 15, 2019
Tue, April 9, 2019
Thu, October 25, 2018
Tue, October 16, 2018
Tue, August 28, 2018
Mon, August 13, 2018
Thu, August 9, 2018
Fri, May 4, 2018
Fri, February 9, 2018
Thu, February 1, 2018
Fri, September 22, 2017
Fri, September 8, 2017
Mon, April 17, 2017
Wed, March 29, 2017
Tue, April 12, 2016
Thu, April 7, 2016
Tue, October 7, 2014

Do Kim Maintained (TVTX) at Buy with Increased Target to $46 on, Feb 21st, 2023


Published on 2024-10-28 01:46:53 - WOPRAI, Do Kim
  Print publication without navigation


Do Kim of Piper Sandler, Maintained "Travere Therapeutics, Inc." (TVTX) at Buy with Increased Target from $42 to $46 on, Feb 21st, 2023.

Do has made no other calls on TVTX in the last 4 months.



There are 2 other peers that have a rating on TVTX. Out of the 2 peers that are also analyzing TVTX, 1 agrees with Do's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Alex Thompson of "Stifel" Initiated at Hold and Held Target at $22 on, Wednesday, December 14th, 2022


This is the rating of the analyst that currently disagrees with Do


  • Edward Nash of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $40 on, Monday, January 30th, 2023